Full Press Release Details
Calling all Veterinarians and Pet Lovers - Take the "Defend Puppies. Defeat Parvo." Pledge Today to Save Puppies from Deadly Canine Parvovirus
GREENFIELD, Ind. , Jan. 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN ) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary death from the highly contagious canine parvovirus (parvo). The Defend Puppies. Defeat Parvo. mission seeks to conquer a virus that, without timely and aggressive care, has a mortality rate as high as 91% 1 . An estimated 900 dogs are diagnosed with parvo daily 2 in the U.S. – mostly unvaccinated puppies. Yet Elanco research revealed only 44% of dog owners know what parvo is, with 20% having no knowledge of the disease. 3 With dog owners being the first line of defense in protecting their puppies, there is need for more wide-spread education.
With the introduction of the Defend Puppies. Defeat Parvo. mission, Elanco aims to increase education about this deadly disease, while increasing veterinarian's access to the first and only U.S. Department of Agriculture (USDA) conditionally approved treatment for parvo – Elanco's Canine Parvovirus Monoclonal Antibody .
The Defend Puppies. Defeat Parvo. mission strengthens Elanco's ability to reach more puppies, more quickly and includes the following:
Notable names already committed to the Parvo Defenders Task Force include:
"Parvo doesn't have to be a death sentence. Our innovative treatment for parvovirus can help veterinarians and pet owners alleviate the emotional toll associated with parvo," said Dr. Jennifer Miller , technical veterinarian with Elanco. "Elanco's Canine Parvovirus Monoclonal Antibody is redefining how we treat the disease, but we can't defeat parvo alone. We're calling all veterinarians and dog lovers to join our mission and help us save more dogs, more quickly. Together, we can save 1 million puppies by 2030."
Clinical efficacy studies demonstrate that Elanco's Canine Parvovirus Monoclonal Antibody delivers targeted efficacy in stopping parvo by blocking its entry into host cells in a puppy's body through a single, intravenous dose. Results have been highly encouraging. In clinical efficacy studies, zero dogs treated with Elanco's Canine Parvovirus Monoclonal Antibody died, and the Canine Parvovirus Monoclonal Antibody treatment helped shorten the course of parvo, helping these puppies feel better, faster.
"I'm hoping that the canine parvovirus monoclonal antibody will become the standard of care," said Dr. Fred Metzger , task force member. "If we make it our first line of therapy, I think you could divert cases away from the ER and back to the private practitioner, where we can treat a large number of parvo puppies that are not even being looked at right now. I'm hoping it will free up emergency clinics a little bit more to really handle the cases that need more immediate care. I see no reason why the canine parvovirus monoclonal antibody wouldn't be the standard of care moving forward."
For more information about the Elanco Defend Puppies. Defeat Parvo. mission, Elanco's Canine Parvovirus Monoclonal Antibody and to Take the Pledge, click here (DefeatParvo.com).
I pledge to forever keep puppies safe. I pledge to lead by example, spreading the word about parvo, its symptoms and treatment. I pledge, because I know together, we can save 1 million puppies from parvo by 2030.
Elanco Animal Health Incorporated (NYSE: ELAN ) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at elanco.com .
©2024 Elanco or its affiliates. Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-23-2394
1 Sykes, JE. Canine Parvovirus Infections and Other Viral Enteritides. Canine and Feline Infectious Diseases. 2014:141-151 2 Elanco Animal Health. Data on File. 3 Elanco Animal Health. Market Data on File.
Investor Contact: Katy Grissom (317) 273-9248 [email protected] Media Contact: Season Solorio (765) 316-0233 [email protected]
SOURCE Elanco Animal Health